A case report indicates that valbenazine may be an effective therapy for chorea-ballism associated with tardive dyskinesia. Valbenazine has therapeutic potential to improve chorea-ballism associated ...

Please provide your email address to receive an email when new articles are posted on . The new once-daily tablet strength doses are 30 mg, 36 mg, 42 mg and 48 mg. Symptom improvement in tardive ...

In 2024, several research and pharmacological advancements were made for tardive dyskinesia, a movement disorder caused by dopamine-blocking medications. Below are some of the highlights of the year.

Credit: FDA. The new sprinkle formulation is intended to be opened for sprinkling on soft foods prior to administration. The Food and Drug Administration (FDA) has accepted for review the New Drug ...

The US Food and Drug Administration (FDA) has approved deutetrabenazine extended-release tablets (Austedo XR, Teva), a new once-daily formulation of the drug for adults with tardive dyskinesia (TD) or ...

Ingrezza (valbenazine) is a prescription drug that’s used to treat certain movement disorders. The drug comes as an oral capsule. It’s usually taken once per day. Specifically, Ingrezza is used in ...

Austedo, a vesicular monoamine transporter 2 (VMAT2) inhibitor, was initially approved to treat Huntington's chorea in April 2017. Teva announced that the Food and Drug Administration (FDA) has ...

Teva’s Austedo is now the first and only therapy approved in the US to treat both tardive dyskinesia and chorea associated with Huntington’s disease. Teva’s Austedo is now the first and only therapy ...

SAN DIEGO, March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT ® 4 study demonstrating remission of tardive ...

Dose proportionality and bioequivalence studies demonstrate once-daily AUSTEDO XR is therapeutically equivalent to twice-daily AUSTEDO® (deutetrabenazine) tablets The U.S. Food and Drug Administration ...

Differentiating tardive dyskinesia from other movement disorders can be challenging. "One major criterion is the history of exposure to neuroleptic medications," said Jeff Bronstein, MD, PhD, of the ...

Please provide your email address to receive an email when new articles are posted on . Teva Pharmaceuticals announced FDA approval of Austedo XR, a once-daily, extended-release formulation for adults ...